ALNY vs EDIT · P/E 76, rev $2.25B vs rev $32.3M
Alnylam Pharmaceuticals Inc (ALNY) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Latest reported ALNY revenue for 2024-12-31 was $2.25B. Net income was -$278.2M. Revenue was up 23.0% from 2023-12-31 to 2024-12-31. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. EDIT currently screens at market cap $375.2M.
Not investment advice. Open the ALNY and EDIT stock pages for the full models.
Not investment advice.